Sign Up Now to Download a Free Research Report on VVUS

Vivus, Inc.

VIVUS, a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, recently reported its financial results for the first quarter ended March 31, 2012. For the quarter ended March 31, 2012, VIVUS had a net loss of $18.8 million compared to a loss of $9.9 million for the first quarter last year. The increase in net loss was primarily attributable to increased general and administrative expenses from spending on Qnexa precommercialization activities.The FDA is scheduled to decide on Vivus’s Qnexa by July 17.

Going forward... (see research report)